Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p

Neben, Kai; M. Lokhorst, Henk; Jauch, Anna; Bertsch, Uta; Hielscher, Thomas; van der Holt, Bronno; Salwender, Hans; Wolfgang Blau, Igor; Weisel, Katja; Pfreundschuh, Michael; Scheid, Christof; Dührsen, Ulrich; Lindemann, Walter; Schmidt‐Wolf, Ingo; Peter, Norma; Teschendorf, Christian; Martin, Hans; Haenel, Mathias; Guenter Derigs, Hans; S. Raab, Marc; D. Ho, Anthony; van de Velde, Helgi; Hose, Dirk; Sonneveld, Pieter; Goldschmidt, Hartmut

doi:10.1182/blood-2011-09-379164

Public

Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p

Published in Blood • Dec 8, 2011

Authors:

Kai Neben

Henk M. Lokhorst

Anna Jauch

Abstract

In patients with multiple myeloma (MM), risk stratification by chromosomal abnormalities may enable a more rational selection of therapeutic approaches. In the present study, we analyzed the prognostic value of 12 chromosomal abnormalities in a series of 354 MM patients treated within the HOVON-65/G...

Subject

Bortezomib

Multiple myeloma

Medicine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!